Why the study?
Does verapamil 120 mg thrice daily improve anginal threshold and ischemic ST segment changes during exercise in patients with ischemic heart disease?
Does verapamil 120 mg thrice daily improve anginal threshold and ischemic ST segment changes during exercise in patients with ischemic heart disease?
Verapamil 360 mg/day is an effective and well-tolerated antianginal agent that improves exercise-induced ischemia and anginal threshold in patients with ischemic heart disease.
Answers are grounded in this paper and cite their sources.
May support verapamil in angina; hypothesis-generating from small cohort and requires RCT confirmation.
Summary The efficacy of verapamil in a dose of 120 mg thrice daily was assessed by an objective protocol. Twenty-five patients with ischaemic heart disease were subjected to serial, measured multistage treadmill exercise without any drugs, and after propranolol 40 mg t.d.s. for 3 days to assess the stress response to beta-blockade. The tests were repeated after 2, 4 and 8 weeks of verapamil. The assessment was based on computerized ST segment changes, the anginal threshold and other objective parameters. Verapamil rendered eight out of thirteen symptomatic patients pain free and significantly increased the anginal threshold in all others. The ischaemic response as assessed by the ST segment changes on exercise showed a marked improvement in the symptomatic as well as the asymptomatic groups. No major side effects were encountered throughout the study. It was concluded that verapamil in a dose of 360 mg/day is an effective antianginal agent free from significant side effects.
No takes yet. Share an insight, caveat, or question.
Balasubramanian et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: